Adapting the Lung Cancer Symptom Scale (LCSS) to mesothelioma: Using the LCSS-Meso conceptual model for validation

Cancer

Volumn 101, Issue 3, 2004, Pages 587-595

  Hollen, Patricia J ^a   Gralla, Richard J ^b   Liepa, Astra M ^c   Symanowski, James T ^c   Rusthoven, James J ^c  

^a UNIVERSITY OF VIRGINIA   (United States)

^b New York Lung Cancer Alliance   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

LCSS Meso; Lung Cancer Symptom Scale; Mesothelioma; Nonsmall cell lung cancer; Quality of life

Indexed keywords

PEMETREXED;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER STAGING; DISTRESS SYNDROME; DYSPNEA; FATIGUE; FEMALE; HEMOPTYSIS; HUMAN; INOPERABLE CANCER; LUNG CANCER; LUNG CANCER SYMPTOM SCALE; MAJOR CLINICAL STUDY; MALE; PAIN; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; QUALITY OF LIFE; RELIABILITY; SCORING SYSTEM; STATISTICAL ANALYSIS; SYMPTOMATOLOGY;

ADULT; AGED; AGED, 80 AND OVER; CLINICAL TRIALS; COHORT STUDIES; DRUG RESISTANCE, NEOPLASM; FEMALE; GLUTAMATES; GUANINE; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM STAGING; PALLIATIVE CARE; PLEURAL NEOPLASMS; PROBABILITY; PROGNOSIS; QUALITY OF LIFE; RISK ASSESSMENT; SICKNESS IMPACT PROFILE; SURVIVAL ANALYSIS; TERMINALLY ILL; TREATMENT OUTCOME;

EID: 3242807430     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20315     Document Type: Article

References (38)

1. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636-2644.
2. Johnson JR, Temple R. Food and Drug Administration requirements for approval of new anticancer drugs. Cancer Treat Rep. 1985;69:1155-1157.
3. American Society of Clinical Oncology. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol. 1996;14:671-679.
4. Gralla RJ, Hollen PJ, Eberly S, Cox C. Quality of life score predicts both response and survival in patients receiving chemotherapy for non-small cell lung cancer. 7th MASCC International Symposium, Luxembourg, September 20-23, 1995 [abstract]. Support Care Cancer. 1995;3:378.
5. Langendijk H, Aaronson NK, de Jong JM, et al. The prognostic impact of quality of life assessed with the EORTC QLQ-C30 in inoperable non-small cell lung carcinoma treated with radiotherapy. Radiother Oncol. 2000;55:19-25.
6. Montazeri A, Milroy R, Hole D, et al. Quality of life in lung cancer patients as an important prognostic factor. Lung Cancer. 2001;31:233-240.
7. Burke MT, Gralla R, Kris M, Howard J, Monras P. Subjective evaluation in non-small cell lung cancer: comparison of Karnofsky performance status with a patient generated visual analogue scale measuring activity [abstract]. In: International Association for the Study of Lung Cancer. Proceedings of the 4th World Conference on Lung Cancer, volume 4. Toronto: IASLC, 1985:42.
8. Hollen PJ, Gralla RJ, Kris MG, Potanovich LM. Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale (LCSS). Eur J Cancer. 1993;29A:S51-S58.
9. Hollen PJ, Gralla RJ, Kris MG, Cox C. Quality of life during clinical trials: conceptual model for the Lung Cancer Symptom Scale (LCSS). Support Care Cancer. 1994;2:213-222.
10. Peto J, Hodgson JT, Matthew FE, Jones JR. Continuing increase in mesothelioma mortality in Britain. Lancet. 1995;345:535-539.
11. Antman KH, Schiff PB, Pass HI. Benign and malignant mesothelioma. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology (5th edition). Philadelphia: Lippincott-Raven, 1997:1853-1878.
12. Ryan CW, Herndon J, Vogelzang NJ. A review of chemotherapy trials for malignant mesothelioma. Chest. 1998;113:66S-73S.
13. Sugarbaker DJ, Norberto JJ, Bueno R. Current therapy for mesothelioma. Cancer Control. 1997;4:326-334.
14. Sterman DH, Kaiser LR, Albelda SM. Advances in the treatment of malignant pleural mesothelioma. Chest. 1999;116:504-520.
15. Ruffie P, Feld R, Minkin S, et al. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. J Clin Oncol. 1989;7:1157-1168.
16. Favaretto AG, Aversa SM, Paccagnella A, et al. Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric Phase II study. Cancer. 2003;97:2791-2797.
17. Fizazi K, Doubre H, Le Chevalier T, et al. Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a Phase II study. J Clin Oncol. 2003;21:349-354.
18. Aisner J. Current approach to malignant mesothelioma of the pleura. Chest. 1995;107:332S-344S.
19. Alberts AS, Falkson G, Goedhals L, et al. Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers. J Clin Oncol. 1988;6:527-535.
20. Chahinian AP, Pajak TF, Holland JF, et al. Diffuse malignant mesothelioma: prospective evaluation of 69 patients. Ann Intern Med. 1982;96:746-755.
21. Chailleux E, Dabouis G, Pioche D, et al. Prognostic factors in diffuse malignant pleural mesothelioma: a study of 167 patients. Chest. 1988;93:159-162.
22. Hollen PJ, Gralla RJ, Kris MG. An overview of the Lung Cancer Symptom Scale. In: Cralla RJ, Moinpour CM, eds. Assessing quality of life in patients with lung cancer: a guide for clinicians. New York: NCM Publishers, 1995:57-63.
23. Hollen PJ, Gralla RJ, Kris MG, et al. Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies: psychometric assessment of the Lung Cancer Symptom Scale. Cancer. 1994;73:2087-2098.
24. McCullagh P, Nelder JA. Generalized linear models (2nd edition). London: Chapman & Hall, 1989.
25. 12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol. 2003;21:1556-1561.
26. Boyer MJ, Jassem J, Liepa AM, et al. Symptom and quality of life advantages for pemetrexed + cisplatin versus cisplatin in treatment of malignant pleural mesothelioma [abstract]. Lung Cancer. 2003;41:S19.
27. Gralla R, Hollen P, Liepa A, Rusthoven J. Health-related quality of life of patients with malignant pleural mesothelioma treated with pemetrexed disodium [abstract]. Eur J Cancer. 2001;37:S282.
28. Shin DM, Scagliotti G, Kindler H, et al. A Phase II trial of pemetrexed in malignant pleural mesothelioma (MPM) patients: clinical outcome, role of vitamin supplementation, respiratory symptoms and lung function [abstract]. Proc Am Soc Clin Oncol. 2002;21:294a.
29. Hollen PJ, Gralla RJ, Liepa AM, Rusthoven JJ. Validation of a quality of life instrument for patients with pleural mesothelioma: Lung Cancer Symptom Scale (LCSS). Proc Am Soc Clin Oncol. 2001;20:396a.
30. Hulley SB, Cummings SR, Browner WS, Grady D, Hearst N, Newman TB. Designing clinical research (2nd edition). Philadelphia: Lippincott Williams & Wilkins, 2001.
31. Frank-Stromborg M, Olsen SJ. Instruments for clinical health-care research (2nd edition). Boston: Jones and Bartlett, 1997.
32. Anastasi A. Psychological testing (6th edition). New York: Macmillan, 1988.
33. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM, editor. Evaluation of chemotherapeutic agents. New York: Columbia University Press, 1949:191-205.
34. Simon R, Wittes RE. Methodological guidelines for reports of clinical trials. Cancer Treat Rep. 1985;69:1-3.
35. Hollen PJ, Gralla RJ, Kris MG, Eberly SW, Cox C. Normative data and trends in quality of life from the Lung Cancer Symptom Scale (LCSS). Support Care Cancer. 1999;7:140-148.
36. Nunnally JC, Bernstein IH. Psychometric theory (3rd edition). New York: McGraw-Hill, 1994.
37. Schroeder MA. Diagnosing and dealing with multicollinearity. West J Nurs Res. 1990;12:175-187.
38. Mor V. Cancer patients' quality of life over the disease course: lessons from the real world. J Chronic Dis. 1987;40:535-544.